20222024: Phase 1 multiple-dose study From 2022 through 2024, a 12-week study evaluated once-weekly doses in adults with obesity or overweight
A.P., drafting the part of the article, table, critical review, and final approval of the version to be submitted
Intravenous administration of direct NAD + has been carried out in humans 66,116,117 , but the human trials were conducted in extremely small cohorts
Rakic D, Joksimovic Jovic J, Jakovljevic V, Zivkovic V, Nikolic M, Sretenovic J, Nikolic M, Jovic N, Bicanin Ilic M, Arsenijevic P
Using both tests is important for people with inflammatory conditions (such as inflammatory bowel diseases, rheumatoid arthritis, and chronic kidney disease), since inflammation increases ferritin levels even when iron stores are depleted